Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Launch Of Trastuzumab Deruxtecan (Enhertu)

 We refer to earlier communication dated May 3, 2023 intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Tanstuzumab deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion (Enhertu). With regard to the same, we wish to further update that AstraZeneca Pharma India Limited will launch Enhertu in January, 2024 in India.
20-12-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith the Certificate dated December 4, 2023 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
15-12-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Closure of Trading Window

 This is to inform you that, in accordance with the provisions of SEBI (LODR) Regulations, 2015, read with AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the Equity Shares of the Company will be closed from December 16, 2023 and the same shall reopen after 48 hours from the declaration of Unaudited Financial Results of the Company for the quarter ending December 31, 2023.
15-12-2023

AstraZeneca to buy vaccine developer Icosavax for up to $1.1 billion

 The deal values Icosavax at $15 per share in cash at closing, plus a non-tradable contingent value right for up to $5 per share in cash if certain milestones are met.
12-12-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) and other applicable regulations of SEBI (LODR) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the claimant. Further, subject to completion of required formalities by the claimant, the Company will issue Letter of Confirmation thereof.
11-12-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Astrazeneca Pharma India Limited Receives Permission To Import Pharmaceutical Formulations Of New Drug For Sale Or For Distribution In Form CT-20 From Central Drugs Standard Control Organisation For BREZTRI AEROSPHERE

 This is to inform you that AstraZeneca Pharma India Limited has received permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for Budesonide Ph. Eur 160 mg + Glycopyrronium Ph. Eur 7.2 mcg + Formoterol Fumarate Dihydrate Ph. Eur 5 mcg inhalation preparations (BREZTRI AEROSPHERE).
02-12-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Appointment Of Senior Management Personnel

 Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company has approved the appointment of Mr. Venkat Natarajan as Lead - Market Access with effect from January 2, 2024.
01-12-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Astrazeneca Pharma India Limited Receives Permission To Import Pharmaceutical Formulations Of New Drug For Sale Or For Distribution In Form CT-20 From Central Drugs Standard Control Organisation For Additional Indication Of Olaparib (Lynparza)

 AstraZeneca Pharma India Limited receives permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drug Standard Control Organisation for the additional indication of Olaparib (Lynparza).
21-11-2023

AstraZeneca Pharma India plans to sell its Bengaluru production facility

 AstraZeneca Pharma India will position the manufacturing site for sale in a fully operational manner and begin its search for a buyer who can also act as a Contract Manufacturing Organisation.
17-11-2023
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
16-11-2023
Next Page
Close

Let's Open Free Demat Account